Inclusion Body Myositis (IBM) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Inclusion Body Myositis (IBM) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Inclusion Body Myositis (IBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inclusion Body Myositis (IBM) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Inclusion Body Myositis (IBM) Overview
  3. Therapeutics Development
  4. Pipeline Products for Inclusion Body Myositis (IBM) - Overview
  5. Pipeline Products for Inclusion Body Myositis (IBM) - Comparative Analysis
  6. Inclusion Body Myositis (IBM) - Therapeutics under Development by Companies
  7. Inclusion Body Myositis (IBM) - Therapeutics under Investigation by Universities/Institutes
  8. Inclusion Body Myositis (IBM) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Inclusion Body Myositis (IBM) - Products under Development by Companies
  13. Inclusion Body Myositis (IBM) - Products under Investigation by Universities/Institutes
  14. Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
  • Acceleron Pharma, Inc.
  • Escala Therapeutics, Inc.
  • Milo Biotechnology LLC
  • Nobelpharma Co., Ltd.
  • Novartis AG
  • Orphazyme ApS
  • Ultragenyx Pharmaceutical Inc.

For more information visit http://www.researchandmarkets.com/research/tr966s/inclusion_body

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs